Acquisition from MSD of an API manufacturing business and portfolio of products by Aspen: Conditions precedent met ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen Holdings”) FURTHER ANNOUNCEMENT REGARDING THE ACQUISITION FROM MSD OF AN API MANUFACTURING BUSINESS AND PORTFOLIO OF PRODUCTS BY ASPEN - CONDITIONS PRECEDENT MET Shareholders are referred to the announcement released by Aspen Holdings on 27 June 2013 wherein it was confirmed that the Aspen Group (“Aspen”) had: - signed an agreement with MSD (known as Merck in the United States and Canada) for the acquisition of an active pharmaceutical ingredient (“API”) manufacturing business which manufactures for MSD and the market generally and which is located in the Netherlands with a satellite facility and sales office in the US (“the API Business”); and - reached an agreement on an option to acquire a portfolio of 11 branded finished dose form molecules (“the Products ”) from MSD, covering a diverse range of therapeutic areas and including products that use APIs manufactured by the API Business. (collectively “the Transactions”) Aspen Holdings is pleased to announce that the parties have agreed that all the contractual conditions precedent necessary to implement the acquisition of the API Business have now been met. The API Business has been transferred to Aspen with effect from today’s date. As confirmed in the announcement released on 27 June 2013, the expected effective date of the Products acquisition, through the exercise of the option, is 31 December 2013 and a further announcement will be made once this aspect of the Transactions has been completed. Durban 1 October 2013 Underwriters The Standard Bank of South Africa Limited Bank of America, N.A. Mandated Lead Arrangers and Bookrunners The Standard Bank of South Africa Limited Banc of America Securities Limited Sponsor: Investec Bank Limited Date: 01/10/2013 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.